Comparative Pharmacology
Head-to-head clinical analysis: ATRACURIUM BESYLATE versus METOCURINE IODIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRACURIUM BESYLATE versus METOCURINE IODIDE.
ATRACURIUM BESYLATE vs METOCURINE IODIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and causing skeletal muscle relaxation.
Competitive nicotinic acetylcholine receptor antagonist at the neuromuscular junction, blocking acetylcholine binding and preventing muscle contraction.
0.4–0.5 mg/kg IV bolus for intubation; maintenance: 0.08–0.1 mg/kg IV as needed or infusion 5–10 mcg/kg/min
Initial dose 0.2 mg/kg IV; maintenance doses of 0.1-0.15 mg/kg IV as needed for neuromuscular blockade.
None Documented
None Documented
Terminal elimination half-life is approximately 20 minutes (range 15-25 min) in healthy adults. Clinical context: Recovery from neuromuscular blockade is faster than for nondepolarizing relaxants cleared renally. Half-life may be prolonged in hypothermia or acidosis but is minimally affected by renal or hepatic impairment.
Clinical Note
moderateAtracurium besylate + Tranilast
"Atracurium besylate may increase the neuromuscular blocking activities of Tranilast."
Clinical Note
moderateAtracurium besylate + Tolfenamic acid
"Atracurium besylate may increase the neuromuscular blocking activities of Tolfenamic acid."
Clinical Note
moderateAtracurium besylate + Nimesulide
"Atracurium besylate may increase the neuromuscular blocking activities of Nimesulide."
Clinical Note
moderateAtracurium besylate + Risedronic acid
Terminal elimination half-life: 3-5 hours in patients with normal renal function. Prolonged in renal impairment.
Renal (50-60% unchanged), biliary/fecal (20-30% as metabolites, mainly laudanosine), and Hofmann elimination (non-enzymatic, pH- and temperature-dependent) accounts for approximately 40-50% of clearance.
Renal: 85-90% unchanged; biliary/fecal: <5%.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker
"Atracurium besylate may increase the neuromuscular blocking activities of Risedronic acid."